Cargando…

Differentially Expressed Mitochondrial Proteins in Human MCF7 Breast Cancer Cells Resistant to Paclitaxel

Identification of novel proteins with changed expression in resistant cancer cells could be helpful in elucidation mechanisms involved in the development of acquired resistance to paclitaxel. In this study, we carried out a 2D-PAGE using the mitochondrial-enriched fraction from paclitaxel-resistant...

Descripción completa

Detalles Bibliográficos
Autores principales: Daniel, Petr, Halada, Petr, Jelínek, Michael, Balušíková, Kamila, Kovář, Jan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6628585/
https://www.ncbi.nlm.nih.gov/pubmed/31248089
http://dx.doi.org/10.3390/ijms20122986
_version_ 1783434989967245312
author Daniel, Petr
Halada, Petr
Jelínek, Michael
Balušíková, Kamila
Kovář, Jan
author_facet Daniel, Petr
Halada, Petr
Jelínek, Michael
Balušíková, Kamila
Kovář, Jan
author_sort Daniel, Petr
collection PubMed
description Identification of novel proteins with changed expression in resistant cancer cells could be helpful in elucidation mechanisms involved in the development of acquired resistance to paclitaxel. In this study, we carried out a 2D-PAGE using the mitochondrial-enriched fraction from paclitaxel-resistant MCF7/PacR cells compared to original paclitaxel-sensitive MCF7 breast cancer cells. Differentially expressed proteins were identified employing mass spectrometry. We found that lysosomal cathepsin D and mitochondrial abhydrolase-domain containing protein 11 (ABHD11) had decreased expression in MCF7/PacR cells. On the other hand, mitochondrial carbamoyl-phosphate synthetase 1 (CPS1) and ATPase family AAA-domain containing protein 3A and 3B (ATAD3A, ATAD3B) were overexpressed in MCF7/PacR cells. Further, we showed that there was no difference in localization of CPS1 in MCF7 and MCF7/PacR cells. We demonstrated a significant increase in the number of CPS1 positive MCF7/PacR cells, using FACS analysis, compared to the number of CPS1 positive MCF7 cells. Silencing of CPS1 expression by specific siRNA had no significant effect on the resistance of MCF7/PacR cells to paclitaxel. To summarize, we identified several novel proteins of a mitochondrial fraction whose role in acquired resistance to paclitaxel in breast cancer cells should be further assessed.
format Online
Article
Text
id pubmed-6628585
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-66285852019-08-05 Differentially Expressed Mitochondrial Proteins in Human MCF7 Breast Cancer Cells Resistant to Paclitaxel Daniel, Petr Halada, Petr Jelínek, Michael Balušíková, Kamila Kovář, Jan Int J Mol Sci Article Identification of novel proteins with changed expression in resistant cancer cells could be helpful in elucidation mechanisms involved in the development of acquired resistance to paclitaxel. In this study, we carried out a 2D-PAGE using the mitochondrial-enriched fraction from paclitaxel-resistant MCF7/PacR cells compared to original paclitaxel-sensitive MCF7 breast cancer cells. Differentially expressed proteins were identified employing mass spectrometry. We found that lysosomal cathepsin D and mitochondrial abhydrolase-domain containing protein 11 (ABHD11) had decreased expression in MCF7/PacR cells. On the other hand, mitochondrial carbamoyl-phosphate synthetase 1 (CPS1) and ATPase family AAA-domain containing protein 3A and 3B (ATAD3A, ATAD3B) were overexpressed in MCF7/PacR cells. Further, we showed that there was no difference in localization of CPS1 in MCF7 and MCF7/PacR cells. We demonstrated a significant increase in the number of CPS1 positive MCF7/PacR cells, using FACS analysis, compared to the number of CPS1 positive MCF7 cells. Silencing of CPS1 expression by specific siRNA had no significant effect on the resistance of MCF7/PacR cells to paclitaxel. To summarize, we identified several novel proteins of a mitochondrial fraction whose role in acquired resistance to paclitaxel in breast cancer cells should be further assessed. MDPI 2019-06-19 /pmc/articles/PMC6628585/ /pubmed/31248089 http://dx.doi.org/10.3390/ijms20122986 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Daniel, Petr
Halada, Petr
Jelínek, Michael
Balušíková, Kamila
Kovář, Jan
Differentially Expressed Mitochondrial Proteins in Human MCF7 Breast Cancer Cells Resistant to Paclitaxel
title Differentially Expressed Mitochondrial Proteins in Human MCF7 Breast Cancer Cells Resistant to Paclitaxel
title_full Differentially Expressed Mitochondrial Proteins in Human MCF7 Breast Cancer Cells Resistant to Paclitaxel
title_fullStr Differentially Expressed Mitochondrial Proteins in Human MCF7 Breast Cancer Cells Resistant to Paclitaxel
title_full_unstemmed Differentially Expressed Mitochondrial Proteins in Human MCF7 Breast Cancer Cells Resistant to Paclitaxel
title_short Differentially Expressed Mitochondrial Proteins in Human MCF7 Breast Cancer Cells Resistant to Paclitaxel
title_sort differentially expressed mitochondrial proteins in human mcf7 breast cancer cells resistant to paclitaxel
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6628585/
https://www.ncbi.nlm.nih.gov/pubmed/31248089
http://dx.doi.org/10.3390/ijms20122986
work_keys_str_mv AT danielpetr differentiallyexpressedmitochondrialproteinsinhumanmcf7breastcancercellsresistanttopaclitaxel
AT haladapetr differentiallyexpressedmitochondrialproteinsinhumanmcf7breastcancercellsresistanttopaclitaxel
AT jelinekmichael differentiallyexpressedmitochondrialproteinsinhumanmcf7breastcancercellsresistanttopaclitaxel
AT balusikovakamila differentiallyexpressedmitochondrialproteinsinhumanmcf7breastcancercellsresistanttopaclitaxel
AT kovarjan differentiallyexpressedmitochondrialproteinsinhumanmcf7breastcancercellsresistanttopaclitaxel